Test fexofenadine for motor improvement
- Trial ID
- NCT06785298
- Official Title
- Clinical Study to Evaluate the Possible Efficacy and Safety of Fexofenadine in Patients With Parkinson's Disease Treated With Conventional Treatment
- Goal
- Test fexofenadine for motor improvement
- Phase
- PHASE2, PHASE3
- Status
- RECRUITING
- Sponsor
- Tanta University
- Study Type
- INTERVENTIONAL
- Enrollment
- 46 participants
- Conditions
- Parkinson Disease
- Interventions
- Levodopa/carbidopa, Fexofenadine
Plain-Language Summary
The goal is to see whether adding fexofenadine to standard levodopa/carbidopa can safely improve Parkinson's symptoms or the overall response to dopamine replacement, while checking for side effects. Fexofenadine is an oral, non-sedating H1 antihistamine that blocks peripheral histamine receptors and has minimal brain penetration, so the trial is testing whether blocking histamine signaling outside the brain changes motor or non-motor symptoms, affects levodopa-related effects, or reduces inflammation without causing sedation or drug interactions. They're enrolling men and women age 50 to 70 with Parkinson's at Hoehn and Yahr stages 1 to 4 who are already on dopamine replacement, excluding people with atypical parkinsonism, significant liver, kidney, or heart problems, pregnancy or breastfeeding, substance abuse, or known allergy to the medications.
Locations
- Tanta University, Tanta, Egypt
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Levodopa/carbidopa. The goal is to see whether adding fexofenadine to standard levodopa/carbidopa can safely improve Parkinson's symptoms or the overall response to dopamine replacement, while checking for side effects. Fexofenadine is an oral, non-sedating H1 antihistamine that blocks peripheral histamine receptors and has minimal brain penetration, so the trial is testing whether blocking histamine signaling outside the brain changes motor or non-motor symptoms, affects levodopa-related effects, or reduces inflammation without causing sedation or drug interactions. They're enrolling men and women age 50 to 70 with Parkinson's at Hoehn and Yahr stages 1 to 4 who are already on dopamine replacement, excluding people with atypical parkinsonism, significant liver, kidney, or heart problems, pregnancy or breastfeeding, substance abuse, or known allergy to the medications.
- Who can participate?
- Participants must be between 50 Years and 70 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This Phase 2/Phase 3 trial is estimated to last approximately 2 years.